E7BE221B-273D-4C04-BE79-366E6455EFBC
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 34.88830486202365
- age_years
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.611
- INTERFERON_ALPHA_RESPONSE+0.547
- OXIDATIVE_PHOSPHORYLATION+0.540
- E2F_TARGETS+0.526
- DNA_REPAIR+0.517
- MYC_TARGETS_V2+0.491
- MTORC1_SIGNALING+0.463
- INTERFERON_GAMMA_RESPONSE+0.446
- GLYCOLYSIS+0.439
- UNFOLDED_PROTEIN_RESPONSE+0.436
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.379
- KRAS_SIGNALING_DN-0.325
- UV_RESPONSE_DN-0.271
- MYOGENESIS-0.262
- APICAL_SURFACE-0.260
- ESTROGEN_RESPONSE_EARLY-0.209
- MITOTIC_SPINDLE-0.141
- APICAL_JUNCTION-0.127
- HEME_METABOLISM-0.067
- SPERMATOGENESIS-0.049
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.970 |
| 2 | 6410821A-1C6A-4F64-939F-196313B8F1E5 | — | — | 0.963 |
| 3 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.961 |
| 4 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.959 |
| 5 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.955 |
| 6 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.951 |
| 7 | A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9 | — | — | 0.947 |
| 8 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.945 |
| 9 | B99430AD-6309-4B90-A0AA-A5B2FA746246 | — | — | 0.945 |
| 10 | E89DB941-19C3-4CD9-9117-EAAF3B2AFD76 | — | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.611 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.547 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.526 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.517 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.491 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.463 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.446 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.439 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.436 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.413 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.407 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.395 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.381 | Idelalisib | — uncovered |
| HYPOXIA | 0.372 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.362 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.353 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.338 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.329 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.326 | Idelalisib | — uncovered |